Sonus Pharmaceuticals gets patent for fluorohydrocarbon echo agents:
This article was originally published in Clinica
Executive Summary
Sonus Pharmaceuticals has received a US patent for fluorohydrocarbon microbubble contrast agents. The patent, Sonus' second for its High-Q Factor technology, covers fluorine-containing hydrocarbons generally and perfluoroethane, perfluoropropane, perfluorobutane and dodecafluoropentane in particular.